U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07112651) titled 'Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause' on Aug. 02.

Brief Summary: This study is to evaluate the effects of CL25216 on vasomotor symptoms in women during Perimenopause. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.

Study Start Date: Aug. 18

Study Type: INTERVENTIONAL

Condition: Vasomotor Symptoms

Intervention: DIETARY_SUPPLEMENT: CL25216

250mg to take one capsule a day after breakfast for 105 days

DIETARY_SUPPLEMENT: Placebo

One capsule a day after breakfast for 105 days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ApexCPG LLC

Disclaimer: Curated by HT Syndicati...